MMMaite Sainz de la Maza

Maite Sainz de la Maza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maite Sainz de la Maza has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Endoretinal biopsy outcomes in suspected vitreoretinal lymphoma after inconclusive vitreous cytology

    by L. Giralt, A. Parrado-Carrillo, N. Vidal-Robau, A. Casablanca-Piñera, J. Nogués-Castell, L. Miguel-Escuder, A. Moll-Udina, O. Balagué, M. Sainz-De-La-Maza, V. Llorenç, et al.

  • Clinical Course and Outcomes of Autoimmune Versus Non-Autoimmune Surgically Induced Scleral Necrosis: A Multicentric Comparative Study

    by Raul E. Ruiz-Lozano, Eugenia M. Ramos-Dávila, Maria F. Colorado-Zavala, Manuel E. Quiroga-Garza, Nadim S. Azar, Hazem M. Mousa, Victor L. Perez, Maite Sainz-De-La-Maza, C. Stephen Foster, Alejandro Rodriguez-Garcia

    To analyze the clinical course and outcomes of autoimmune vs. non-autoimmune surgically induced scleral necrosis (SISN). Multicentric, retrospective, comparative cohort study. Eighty-two eyes of 70 patients with SISN were classified according to pathogenic mechanism into autoimmune vs. non-autoimmune. Main outcome measures included necrosis onset, type of surgery, associated systemic disease, visual acuity, and treatment were analysed in patients followed for ≥ 6 months. Forty-six (65.7%) patients were women, and the median age was 66 (range: 24-90) years. Most patients (82.9%) had unilateral disease. The median time between surgery and SISN onset was 58 (1-480) months. Thirty-one (37.8%) eyes were classified as autoimmune, and 51 (62.2%) as non-autoimmune SISN. Autoimmune SISN was associated with a shorter time between the surgical procedure and SISN onset than non-autoimmune cases (median of 26 vs. 60 months, p = 0.024). Also, autoimmune SISN was associated with cataract extraction (93.5% vs. 25.5%, p < 0.001), severe scleral inflammation (58.1% vs. 17.6%, p < 0.001), and higher incidence of ocular complications (67.7% vs. 33.3%, p = 0.002) than non-autoimmune cases. Remission was achieved with medical management alone in 44 (86.3%) eyes from the non-autoimmune and in 27 (87.1%) from the autoimmune group (p = 0.916). Surgical management was required in 11 (13.4%) eyes, including two requiring enucleations due to scleral perforation and phthisis bulbi. Eyes with autoimmune SISN had a higher rate of cataract surgery, severe scleral inflammation, and ocular complications. Early SISN diagnosis and appropriate management, based on clinical features and pathogenic mechanisms, are critical to avoid sight-threatening complications.


  • Ocular Mucous Membrane Pemphigoid

    by Raul E. Ruiz-Lozano, Maria F. Colorado-Zavala, Eugenia M. Ramos-Dávila, Manuel E. Quiroga-Garza, Nadim S. Azar, Hazem M. Mousa, Julio C. Hernández-Camarena, Sandra S. Stinnett, Melissa Daluvoy, Terry Kim, et al.


  • Non‐invasive biomarkers for close activity monitoring in birdshot chorioretinitis: Optical coherence tomography angiography and beyond

    by Aina Moll‐Udina, Marina Dotti‐Boada, Lucía Miguel, Anabel Rodríguez, Jesús Gascón, Maite Sainz de la Maza, Alfredo Manuel Adán Civera, Blanca Molins, Victor Llorenç

    Purpose: The purpose of the study was to identify non-invasive imaging biomarkers potentially useful for close activity monitoring in birdshot chorioretinitis (BSCR). Methods: Cross-sectional study of BSCR eyes included as per Levinson's and/or SUN criteria. Eyes were blindly classified into active or inactive groups per clinical inflammatory parameters, ultra-widefield (UWF) pseudocolour images, UWF fluorescein angiography (FA) and macular optical coherence tomography (OCT) cube. Qualitative and quantitative OCT and OCT-angiography (OCT-A) parameters at the fundus, superonasal and inferonasal fields were compared between active and inactive eyes. Results: Thirty consecutive BSCR patients (60 eyes) were analysed. 28 eyes (46.66%) were from women and the overall mean age was 59.7 +/- 12.3 years. Active eyes showed an abnormal retinal thickening at inferonasal field (nasal retinal thickness) and a higher averaged thickened retinal index (ATRI) (72.36 active vs. 20.12 inactive, p < 0.0001). A significant moderate correlation was observed between ATRI and FA scores (r = 0.259, p = 0.022). Macular vascular loops were more frequent in the superficial vascular plexus of OCT-A in the active eyes (p = 0.028). The vascular perfusion index tended to be higher in all subfields of active eyes but did not reach statistical significance. Conclusion: Multimodal imaging could be key to discerning activity in BSCR eyes. Higher ATRI and the presence of vascular loops in the superficial plexus are potential non-invasive activity biomarkers for the close monitoring of BSCR.


  • Presumed tuberculosis-related scleritis

    by Maite Sainz de La Maza, Ines Hernanz, Aina Moll-Udina, Marina Mesquida, Alfredo Adan, Jose Antonio Martinez, Gerard Espinosa, Víctor Llorenç

    Aims To evaluate the clinical characteristics and therapeutic outcome of patients with recurrent scleritis of unknown demonstrable aetiology and positive QuantiFERON-TB Gold In-Tube test (QFT). Methods Retrospective chart review of the demographic, clinical, laboratory and therapeutic outcome data of 15 patients. Clinical characteristics as well as remission rate after standard antituberculous therapy (ATT) were assessed. Results There were 9 men and 6 women with a mean age of 48.9 years (range, 32–73). Scleritis was diffuse in 10 patients (66.6%) and nodular in 5 patients (33.3%), 1 of them with concomitant posterior scleritis. It was bilateral in 7 patients (46.6%) and recurrent in all of them. Scleritis appeared after prior uveitis (10 patients, 66.6%) and/or with concomitant uveitis (5 patients, 33.3%) or peripheral keratitis (5 patients, 33.3%). Previous ocular surgery was found in 7 patients (46.6%). Previous extraocular tuberculosis (TB) infection or previous TB contact was detected in 11 patients (73.3%). No radiologic findings of active extraocular TB were detected. ATT was used in 15 patients, sometimes with the addition of systemic corticosteroids (5 patients) and methotrexate (1 patient); 14 patients achieved complete remission (93.3%). Conclusion Presumed TB-related scleritis may appear in recurrent scleritis of unknown origin and positive QFT. It may occur after prior uveitis and/or concomitantly with uveitis or peripheral keratitis, and it may be triggered by previous ocular surgery. No patients had evidence of concurrent active extraocular infection, although many had previous TB infection or TB contact. ATT was effective, sometimes with the addition of systemic corticosteroids and methotrexate.


  • Anterior segment involvement in Epstein–Barr virus: a review

    by Carmen Alba‐Linero, Carlos Rocha‐De‐Lossada, Rahul Rachwani‐Anil, Maite Sainz‐De‐La‐Maza, Gabriel Sena‐Corrales, Vito Romano, Marina Rodríguez‐Calvo‐De‐Mora

    The aim of this study is to describe the involvement of Epstein–Barr Virus (EBV) in the diseases of the ocular anterior segment. This is a narrative review designed using the PUBMED, SCOPE and Web of Science databases, searching for reported literature on findings in the anterior ocular segment related to EBV between 1990 and 2020. Epstein–Barr Virus (EBV) is implicated in the development of salmon‐coloured conjunctival masses in the context of acute mononucleosis and lymphoproliferative disorders. Moreover, EBV can cause haemorrhagic conjunctivitis and its corneal implications appear as different types of keratitis patterns. The involvement of EBV in the pathogenesis of anterior segment inflammation is not well‐defined. Current evidence regarding anterior segment disease caused by EBV infection has been proved by positive viral detection through polymerase chain reaction test in eyes with lymphoproliferative disorders known to be caused by EBV, as B‐ and NK/T‐cell lymphoid tumours. Antiviral treatment (oral Aciclovir or Valaciclovir) in anterior segment disease caused by EBV remains controversial.


  • Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis

    by Lucia Miguel-Escuder, Amanda Garcia Tirado, María Sainz-De-La-Maza, Gerard Espinosa, Aina Moll-Udina, Víctor Llorenç, Alba Parrado-Carrillo, Alfredo Adán

    Purpose: Anti-TNF-α-induced lupus (ATIL) is a rare condition considered as a drug-induced lupus (DIL) in patients under anti-TNF-α therapies. Nowadays it is still unclear if ATIL is a classical DIL or represent a distinct syndrome. Some characteristics of DIL have been described specifically associated with patients with lupus-like syndrome receiving anti-TNF-α therapy: the severity of the disease, incidence/prevalence of dsDNA antibodies (anti-dsDNA) and hypocomplementaemia. The objective of this study is to describe the development of ATIL in patients with non-infectious uveitis in a single tertiary center. Methods: Retrospective description of a case series. Results: We describe three patients with noninfectious uveitis (NIU) of different etiologies who developed antinuclear antibody (ANA) and anti-dsDNA antibody positivity, arthritis and, in one case, skin lesions under adalimumab treatment. The condition resolved in all of them after adalimumab withdrawal. Corticosteroids were required in one patient, non-steroidal anti-inflammatory drugs in two patients, and hydroxychloroquine in one of them. None required another immunosuppressive drug. A subsequent control of the NIU could continue to be carried out without anti-TNF-α therapy in two patients and in the remaining a switch was made to another anti-TNF-α (golimumab). Conclusion: The current report describes three cases of ATIL in patients with different types of NIU which share some common features: ANA positivity, articular symptoms, and a temporal relationship between symptoms onset and anti-TNF-α treatment. A review of the literature and comparison with the few previous reported ATIL cases was conducted as well.


  • Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy

    by Aina Moll-Udina, Lucía Miguel Escuder, Inés Hernanz, Victor Llorenç, Alex Fonollosa, Miguel Cordero Coma, Maite Sainz de la Maza, Gerard Espinosa, J. Jacobo González Guijarro, Fernando Lopez Lopez, et al.

    To assess the efficacy and safety of adalimumab in elderly patients with noninfectious uveitis (NIU). An observational, retrospective, multicenter study was done. Changes in best-corrected visual a...


  • Open Access

    New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

    by Claudia Fabiani, Jurgen Sota, Maite Sainz-De-La-Maza, Laura Pelegrín, Giacomo Emmi, Giuseppe Lopalco, Florenzo Iannone, Lorenzo Vannozzi, Silvana Guerriero, Maria Chiara Gelmi, et al.

    Objective. To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-) α inhibitors, in the management of noninfectious refractory scleritis, either idiopathic or associated with systemic immune-mediated disorders. Patients and Methods. This is a retrospective study assessing the efficacy of several biologic agents (rituximab, anakinra, tocilizumab, and abatacept) and the small molecule tofacitinib in the treatment of scleritis through assessment of scleral inflammation and relapses, as well as treatment impact on best-corrected visual acuity (BCVA) and safety profile. Results. Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (p=0.002) and from baseline to the last follow-up visit (p=0.002). Scleritis relapses significantly decreased between the 12 months preceding and following biologic therapy (p=0.007). No differences regarding BCVA were observed (p=0.67). Regarding adverse events, only one patient developed pneumonia and septic shock under rituximab treatment. Conclusions. Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses.


  • Open Access

    Clinical Features of Primary and Systemic Metastatic Intraocular Lymphomas in Spanish Patients

    by Victor Llorenç, Carla Fuster, Carmen Alba-Linero, Aina Moll-Udina, Alba Serrano, Manel Solé, Maite Sainz de la Maza, Iban Aldecoa, Alfredo Adán

    Objectives. To describe and compare clinical findings in different subtypes of biopsy-proven intraocular lymphomas (IOLs). Design. Retrospective, observational case series. Methods. The clinical and pathologic features in IOLs at the Hospital Clinic of Barcelona from 1995 to 2018 were retrospectively studied. Results. Twenty-one patients, 12 men (57%), median age 60 (interquartile range, IQR: 18 years), and a median follow-up of 30 (IQR 60) months were included. Eleven patients had primary vitreo-retinal lymphoma (PVRL, 52%), 4 had primary uveal lymphoma (PUL, 19%), and 6 had systemic metastatic retinal lymphomas (SMRLs, 28%). Diffuse large B-cell lymphoma was the main IOL subset in PVRL (91%) and in SMRL (83%), whereas extranodal marginal zone lymphoma was the only type in PUL (100%). Survival rate was 44% in PVRL and 20% in SMRL at 5 years (p=0.047). One patient had flow cytometry of two different vitreous humour samples. With them, flow cytometry was performed in a total of 11 samples, yielding 7 positive samples. Conclusions and Relevance. Even though PVRL is the most frequent IOL subtype, our findings suggest that PUL and SMRL should be considered as potential IOL causes. Overall survival was poor in PVRL and even shorter in SMRL patients.